Precision BioSciences Announces Presentations at the 14th Annual Terrapinn World Advanced Therapies & Regenerative Medicine Congress & Expo 2019
DURHAM, North Carolina, May 09, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS® genome…
Precision BioSciences Announces Presentations at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy
DURHAM, North Carolina, April 24, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS® genome…
Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial
First NHL patient treated with allogeneic CAR T in US-based trial DURHAM, North Carolina, April 17, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company…
Precision BioSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
DURHAM, North Carolina, April 1, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome…
Elo Life Systems Announces a Collaboration With Ashland Subsidiary Avoca to Scale a Sustainable, Key Input for Fragrances
DURHAM, NORTH CAROLINA – February 25, 2019 – Elo Life Systems Inc. announced today a collaboration with Avoca LLC, a subsidiary of the specialty chemicals company Ashland, that is focused on…
Science Article About the Quest to Cure HBV Brings Context to Precision BioSciences Collaboration With Gilead
Precision BioSciences is pleased to be part of this important feature story from Science Magazine: Forgotten No More – A long-overlooked scourge of millions, hepatitis B is in the crosshairs…
Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
FOSTER CITY, Calif. and DURHAM, NC, Sept 12, 2018 – Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to…
Penn Announces Publication of Clinically Relevant Genome Editing in Primates Using Precision's ARCUS Platform
Durham, NC July 09, 2018 – The University of Pennsylvania’s Perelman School of Medicine announced today that researchers from Jim Wilson’s Gene Therapy Program have found that using…
Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs
DURHAM, North Carolina, USA, June 26 2018 –Precision BioSciences today announced the closing of an oversubscribed $110M Series B financing to further product development efforts based on its ARCUS®…
Precision BioSciences CSO to Join Gene Therapy Session at DIA 2018
DURHAM, North Carolina, USA, June 20 2018 – Precision BioSciences CSO Derek Jantz will present and join a panel discussion during the DIA (Drug Information Association) 2018 conference session #285,…
Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
DURHAM, North Carolina, USA, May 14 2018 – Precision BioSciences, the ARCUS genome editing company with novel product development programs in gene therapy, cancer immunotherapy and non-GMO food,…
Precision BioSciences Announces Appointment of Gene Liau, Ph.D. and Bruce McCreedy, Ph.D. to Management Team
RESEARCH TRIANGLE PARK, North Carolina, September 2nd, 2015 – Precision BioSciences, the genome editing company, today announced two key additions to the executive team – Gene Liau, Ph.D., as Senior…